Get the Stockscreener App
61.94
0.34%
-0.19
Apogee Therapeutics Inc stock is traded at $61.94, with a volume of 887.04K.
It is down -0.34% in the last 24 hours and down -20.87% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$62.13
Open:
$64.45
24h Volume:
887.04K
Relative Volume:
0.96
Market Cap:
$4.24B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-22.49
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
-5.48%
1M Performance:
-20.87%
6M Performance:
+70.48%
1Y Performance:
+48.70%
1-Day Range:
$61.76
$64.95
1-Week Range:
$61.76
$69.45
52-Week Range:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
62.00 | 4.24B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.73 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.52 | 81.05B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
811.30 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.10 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
352.14 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com - Investing.com Australia
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns By Investing.com - Investing.com Canada
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns - Investing.com
What drives Apogee Therapeutics Inc.’s stock priceEarnings Overview Summary & Low Risk Entry Point Tips - mfd.ru
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Aug Gainers: Can Apogee Therapeutics Inc stock outperform in a bear marketWeekly Stock Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling A 49.24% Upside In Biotech - DirectorsTalk Interviews
Does Apogee Therapeutics Inc. meet Warren Buffett’s criteriaEntry Point & Consistent Return Investment Signals - Mfd.ru
(APGE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Shorts: What are TrueBlue Incs growth leversGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Promising Biotech Stocks To ResearchJanuary 24th - MarketBeat
Aug Breakouts: Whats the RSI of Adicet Bio Inc stockPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million By Investing.com - Investing.com Nigeria
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares - MarketBeat
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns - Investing.com India
RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk - marketscreener.com
Apogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech Gem with a 27.70% Upside Potential - DirectorsTalk Interviews
Bear Alert: Whats the beta of Apogee Therapeutics Inc stock2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Henderson sells $1.6m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.6m in stock - Investing.com
Price-Driven Insight from (APGE) for Rule-Based Strategy - Stock Traders Daily
What are Apogee Therapeutics Incs growth leversJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Apogee's Pipeline Momentum Driving Investor Confidence? - RTTNews
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com - Investing.com Australia
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's Why - MarketBeat
Apogee Therapeutics stock hits all-time high at 81.0 USD - Investing.com
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling a 32.83% Potential Upside Amidst Promising Biotech Innovations - DirectorsTalk Interviews
Published on: 2026-01-13 09:29:07 - Улправда
Apogee Therapeutics Insider Sold Shares Worth $1,455,613, According to a Recent SEC Filing - marketscreener.com
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Yahoo Finance
SG Americas Securities LLC Invests $5.33 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Positive Asthma Data and I&I Pipeline Plans Could Be A Game Changer For Apogee Therapeutics (APGE) - Yahoo Finance
A Look At Apogee Therapeutics (APGE) Valuation After Positive Asthma Trial Update And 2026 Pipeline Milestones - Sahm
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):